Loading stock data…
Lunai Bioworks Inc. (LNAI)
$2.60+0.21 (+8.79%)
Market ClosedLast close Sep 8
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lunai Bioworks Inc. in the Healthcare sector is trading at $2.60 with a market capitalization of $10M. The stock is currently near its 52-week low of $1.21, remaining 39.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20,942 | $0 | $0 | $0 | $0 |
| Gross Profit | $20,942 | — | — | — | $0 |
| Operating Income | -$1.43M↑ | -$1.82M↑ | -$2.48M↑ | -$4.11M↑ | -$4.16M |
| Net Income | -$2.57M↓ | -$1.80M↓ | $2.82M↑ | -$126.73M↓ | $189,176 |
Peer Comparison
JNJUNHPFE
Fundamentals
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
1342.81%
Volume
Today's trading volume
60,642
Recent News
Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?
Lunai Bioworks said Nasdaq confirmed that the company regained compliance with the exchange’s minimum bid price requirement, according to an SEC filing.
BC-Most Active Stocks
Megan Holdings Ltd. 38,029,230 0.4681
Lunai Bioworks: Fiscal Q2 Earnings Snapshot
SACRAMENTO, Calif. AP) — Lunai Bioworks Inc. LNAI) on Tuesday reported a loss of $1.8 million in its fiscal second quarter.
Lunai Bioworks: Fiscal Q1 Earnings Snapshot
LOS ANGELES (AP) — Lunai Bioworks Inc. LNAI) on Friday reported profit of $2.8 million in its fiscal first quarter. On a per-share basis, the Los Angeles-based company said it had net income of 13 cents.